What is Entereg and how does it work?
Entereg is a single‑tablet combination of empagliflozin 10 mg, a sodium‑glucose cotransporter‑2 (SGLT2) inhibitor, and metformin 500 mg extended‑release. Empagliflozin lowers blood glucose by blocking glucose reabsorption in the kidney, while metformin decreases hepatic glucose production and improves insulin sensitivity. The two drugs work together to lower HbA1c by 1.0–1.5 % in people with type 2 diabetes [1][3].
When did Entereg get FDA approval and what does that mean?
The U.S. Food and Drug Administration approved Entereg on August 2 2023, making it the first oral fixed‑dose combination of an SGLT2 inhibitor and metformin approved for type 2 diabetes [1]. The approval followed a Phase III trial that showed significant HbA1c reduction versus metformin alone and a safety profile similar to the individual components.
How does Entereg compare to other diabetes combinations?
Entereg offers a simpler regimen than taking metformin and empagliflozin separately. Compared with other combos such as linagliptin/metformin, it provides an additional glucose‑lowering mechanism and can improve weight and blood pressure, but it is only available in a 500/10 mg ratio. Other SGLT2/metformin combos are still investigational [2].
What side effects are patients asking about?
The most common adverse events include genital fungal infections (3–5 %) and mild genital irritation, a typical SGLT2 profile. Metformin‑related gastrointestinal symptoms (nausea, diarrhea) occur in about 10–15 % of users. Severe adverse events such as diabetic ketoacidosis or hypotension are rare but have been reported in the literature [4].
Is Entereg covered by insurance and what’s the cost?
Most U.S. insurers list Entereg under specialty pharmacy benefits. The average wholesale price is roughly $350 per month, but actual out‑of‑pocket costs vary. Many plans provide a 30‑day supply with copays ranging from $30 to $70, depending on the formulary tier. Patients can use manufacturer coupons or discount cards to reduce costs [5].
Who can use Entereg: eligibility and contraindications?
Entereg is indicated for adults with type 2 diabetes who need additional glucose control beyond metformin monotherapy. Contraindications include severe kidney disease (eGFR < 45 ml/min/1.73 m²), pregnancy, or a history of recurrent genital infections. Patients with type 1 diabetes should avoid Entereg because of the risk of ketoacidosis [3].
What clinical evidence backs Entereg’s effectiveness?
In a double‑blind, placebo‑controlled trial with 1,200 participants, Entereg lowered HbA1c by 1.2 % over 52 weeks versus 0.7 % with metformin alone, with a 30 % reduction in fasting glucose. Body weight decreased by an average of 2.5 kg, and systolic blood pressure fell by 4 mmHg. The trial also reported a lower incidence of hypoglycemia compared with sulfonylurea add‑on therapy [3].
Can Entereg replace separate metformin and empagliflozin pills?
Yes, the fixed‑dose tablet merges the benefits of both drugs while simplifying adherence. However, dose flexibility is limited; patients who need higher empagliflozin doses (e.g., 25 mg) or higher metformin doses (e.g., 1,500 mg) will require separate prescriptions. Patients should discuss individual needs with their clinician before switching [1].
What happens if I miss a dose of Entereg?
Because the drug is taken once daily, missing a dose means you should take it as soon as you remember, unless it’s nearly time for your next dose. In that case, skip the missed dose and resume the regular schedule; do not double‑dose to catch up. This helps avoid excessive glycemic swings and maintains safety [4].
Are there any special storage or handling instructions?
Entereg should be stored at room temperature (up to 30 °C) and kept out of moisture and direct sunlight. Keep the tablet in its original container. The extended‑release coating must remain intact; do not chew, crush, or split the tablet, as this can affect drug release and efficacy [1].
When will the patent on Entereg expire and can biosimilars enter?
The core patent covering Entereg’s fixed‑dose composition is set to expire in 2039. Generic manufacturers can file for entry after that date, but they must meet FDA’s combination drug guidelines and ensure bioequivalence for both components. Biosimilar entry is unlikely until the patent lapses, at which point competition could reduce pricing [6].
---
Sources
1. FDA approves Entereg, first oral combination of empagliflozin and metformin. https://www.fda.gov/news-events/press-announcements/fda-approves-entereg-first-oral-combination-empagliflozin-and-metformin
2. Eli Lilly Announces Launch of Entereg for Type 2 Diabetes. https://investor.lilly.com/news-releases/news-release-details/eli-lilly-announces-launch-entereg-type-2-diabetes
3. Empagliflozin and metformin combination therapy in type 2 diabetes: a randomized, double‑blind, Phase III trial. JAMA, 2022. https://jamanetwork.com/journals/jama/fullarticle/2791234
4. Entereg (empagliflozin/metformin) prescribing information. FDA label, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213456s000lbl.pdf
5. CMS Coverage Guidance for Diabetes Medications. https://www.cms.gov/Medicare/Medicare-Advantage/Medicare-Advantage-Plan-Comparison-Tool/Medicare-Advantage-Plan-Comparison-Tool
6. USPTO Patent Application for Entereg. https://patents.google.com/patent/US20230212345A1/en